𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The economic burden of prostate cancer, California, 1998

✍ Scribed by Wendy Max; Dorothy P. Rice; Hai-Yen Sung; Martha Michel; Wendy Breuer; Xiulan Zhang


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
75 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

Prostate cancer is the most common malignancy diagnosed among men in the United States. This article reviews previous studies of the annual cost of all cancers and of prostate cancer in the United States and California and estimates the direct and indirect costs of prostate cancer in California in 1998.

METHODS

Hospitalization costs, including costs of primary and secondary diagnoses of prostate cancer, were derived from the California Hospital Discharge data set (CHDS). Charges were converted to costs using hospital specific cost‐to‐charge ratios and an imputed cost for Health Maintenance Organization hospitalizations. Other direct medical costs were derived from the 1997 Medical Expenditure Panel Survey. Indirect mortality costs are the product of the number of deaths and the expected value of a male's future earnings taking into account age at death, earning patterns at successive ages, labor force participation, imputed value of housekeeping services, and a 3% discount rate.

RESULTS

Prostate cancer direct health care costs in California were estimated at $180 million, and lost productivity from premature death was estimated at $180 million, for a total cost of $360 million in 1998. The disease is largely one of older men; hospitalization costs account for three‐fifths of total direct costs, and Medicare and private health insurance share almost equally in paying for hospital care.

CONCLUSIONS

It is critical to identify cost‐effective screening efforts that permit early detection of prostate cancer to reduce illness, premature deaths, and the high costs of prostate cancer. Cancer 2002;94:2906–13. Β© 2002 American Cancer Society.

DOI 10.1002/cncr.10532


πŸ“œ SIMILAR VOLUMES


The burdens of cancer therapy : Clinical
✍ Linda S. Elting; Catherine Cooksley; Mark Chambers; Scott B. Cantor; Ellen Manzu πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 119 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Mucositis is a common but poorly studied problem among patients with solid tumors. The authors examined the clinical and economic outcomes of oral and gastrointestinal (GI) mucositis among patients receiving myelosuppressive chemotherapy. ## METHODS A retrospective, ran

The burdens of cancer therapy : Clinical
✍ Kenneth V. I. Rolston πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 45 KB πŸ‘ 1 views

## The Burdens of Cancer Therapy Clinical and Economic Outcomes of Chemotherapy-Induced Mucositis W e read with great interest the article by Elting et al. describing the clinical and economic outcomes of patients with chemotherapyinduced mucositis. 1 Despite the limitation of a retrospective anal

The unequal burden of cancer
✍ David Satcher πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 74 KB πŸ‘ 2 views

T he unequal burden of cancer among ethnic minorities and the medically underserved represents one of public health's most difficult challenges. It will require an unwavering commitment to finding real solutions to address this complex problem. I know that this work can be especially challenging at

The global burden of cancer
✍ Stephen F. Sener; Nathan Grey πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 49 KB
Economic burden of metastatic bone disea
✍ Kathy L. Schulman; Joseph Kohles πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 232 KB

## Abstract ## BACKGROUND Previous research has documented the prevalence of primary bone cancer; however, there are few data available regarding the impact of metastatic bone disease (MBD) on national expenditure. In this study, the authors quantified the prevalence and direct medical care costs